Journal article
Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson’s disease: the PPMI cohort
Journal of neurology, neurosurgery and psychiatry, Vol.89(1), pp.78-88
01/2018
DOI: 10.1136/jnnp-2017-316213
PMCID: PMC5732865
PMID: 28986467
Abstract
ObjectiveTo examine the baseline prevalence and longitudinal evolution in non-motor symptoms (NMS) in a prospective cohort of, at baseline, patients with de novo Parkinson’s disease (PD) compared with healthy controls (HC).MethodsParkinson’s Progression Markers Initiative (PPMI) is a longitudinal, ongoing, controlled study of de novo PD participants and HC. NMS were rated using the Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Part I score and other validated NMS scales at baseline and after 2 years. Biological variables included cerebrospinal fluid (CSF) markers and dopamine transporter imaging.Results423 PD subjects and 196 HC were enrolled and followed for 2 years. MDS-UPDRS Part I total mean (SD) scores increased from baseline 5.6 (4.1) to 7.7 (5.0) at year 2 in PD subjects (p<0.001) versus from 2.9 (3.0) to 3.2 (3.0) in HC (p=0.38), with a significant difference between the groups (p<0.001). In the multivariate analysis, higher baseline NMS score was associated with female sex (p=0.008), higher baseline MDS-UPDRS Part II scores (p<0.001) and more severe motor phenotype (p=0.007). Longitudinal increase in NMS severity was associated with the older age (0.008) and lower CSF Aβ1–42 (0.005) at baseline. There was no association with the dose or class of dopaminergic therapy.ConclusionsThis study of NMS in early PD identified clinical and biological variables associated with both baseline burden and predictors of progression. The association of a greater longitudinal increase in NMS with lower baseline Aβ1–42 level is an important finding that will have to be replicated in other cohorts.Trial registrationClinicalTrials.gov identifier: NCT01141023.
Details
- Title: Subtitle
- Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson’s disease: the PPMI cohort
- Creators
- Tanya Simuni - Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USAChelsea Caspell-Garcia - Department of Biostatistics, University of Iowa, Iowa City, Iowa, USAChristopher S Coffey - Department of Biostatistics, University of Iowa, Iowa City, Iowa, USADaniel Weintraub - University of Pennsylvania School of Medicine and the Parkinson’s Disease and Mental Illness Research, Education and Clinical Centers (PADRECC and MIRECC), Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USABrit Mollenhauer - Center of Parkinsonism and Movement Disorders Paracelsus-Elena Klinik Kassel, University Medical Center Goettingen, Kassel, GermanyShirley Lasch - Institute for Neurodegenerative Disorders, New Haven, Connecticut, USACaroline M Tanner - University of California San Francisco, San Francisco, California, USADanna Jennings - Eli Lilly and Company, Indianapolis, Indiana, USAKarl Kieburtz - University of Rochester Medical Center, Rochester, New York, USALana M Chahine - University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USAKenneth Marek - Institute for Neurodegenerative Disorders, New Haven, Connecticut, USA
- Resource Type
- Journal article
- Publication Details
- Journal of neurology, neurosurgery and psychiatry, Vol.89(1), pp.78-88
- DOI
- 10.1136/jnnp-2017-316213
- PMID
- 28986467
- PMCID
- PMC5732865
- NLM abbreviation
- J Neurol Neurosurg Psychiatry
- ISSN
- 0022-3050
- eISSN
- 1468-330X
- Language
- English
- Date published
- 01/2018
- Academic Unit
- Biostatistics
- Record Identifier
- 9983997326902771
Metrics
28 Record Views